Citigroup Inc Nektar Therapeutics Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Nektar Therapeutics stock. As of the latest transaction made, Citigroup Inc holds 130,122 shares of NKTR stock, worth $118,411. This represents 0.0% of its overall portfolio holdings.

Number of Shares

130,122

Previous 40,150 224.09%

Holding current value

$118,411

Previous $49,000 244.9%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$1.11 - $1.48 $99,868 - $133,158	89,972 Added 224.09%	130,122 $169,000
Q2 2024 Aug 12, 2024	BUY	$0.9 - $1.83 $36,064 - $73,331	40,072 Added 51374.36%	40,150 $49,000
Q1 2024 May 10, 2024	SELL	$0.49 - $0.96 $175,241 - $343,330	-357,636 Reduced 99.98%	78 $0
Q4 2023 Feb 09, 2024	BUY	$0.42 - $0.57 $117,489 - $159,449	279,736 Added 358.74%	357,714 $200,000
Q3 2023 Nov 09, 2023	BUY	$0.51 - $1.05 $37,869 - $77,966	74,254 Added 1993.93%	77,978 $46,000
Q2 2023 Aug 10, 2023	SELL	$0.53 - $1.03 $44,145 - $85,791	-83,293 Reduced 95.72%	3,724 $2,000
Q1 2023 May 11, 2023	SELL	$0.64 - $3.15 $27,251 - $134,127	-42,580 Reduced 32.86%	87,017 $60,000
Q4 2022 Feb 09, 2023	SELL	$2.03 - $4.28 $8,284 - $17,466	-4,081 Reduced 3.05%	129,597 $292,000
Q3 2022 Nov 10, 2022	SELL	$3.04 - $5.14 $132,872 - $224,659	-43,708 Reduced 24.64%	133,678 $428,000
Q2 2022 Aug 10, 2022	SELL	$3.17 - $6.17 $62,410 - $121,474	-19,688 Reduced 9.99%	177,386 $674,000
Q1 2022 May 12, 2022	BUY	$4.16 - $13.72 $321,917 - $1.06 Million	77,384 Added 64.65%	197,074 $1.06 Million
Q4 2021 Feb 10, 2022	BUY	$10.83 - $18.41 $633,598 - $1.08 Million	58,504 Added 95.62%	119,690 $1.62 Million
Q3 2021 Nov 10, 2021	BUY	$13.07 - $18.84 $799,701 - $1.15 Million	61,186 New	61,186 $1.1 Million

Others Institutions Holding NKTR

# of Institutions

145

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $171M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account